HCQ in Resectable Localized Prostate Cancer

Official title

A Randomized, Placebo Controlled Proof of Principle (Window of Opportunity) Study of Hydroxychloroquine (HCQ) in Prostate Cancer Patients Undergoing Radical Prostatectomy

Overview

This is randomized, double blind, placebo controlled proof of principle (window of opportunity) study of oral hydroxychloroquine in patients with resectable localized prostate cancer. To determine the effects of hydroxychloroquine (HCQ) on markers of autophagy, such as p62, LC3-II and NBR-1 in prostate cancer tissue of patients with resectable localized prostate cancer who undergo radical prostatectomy. To monitor/observe the safety and tolerability of daily oral hydroxychloroquine in the pre and perioperative period in patients who undergo radical prostatectomy. To evaluate the concentration of hydroxychloroquine in normal and prostate tumor tissue and to correlate prostate tissue concentrations with the plasma concentrations in these patients. To perform tumor genomic analysis (for common somatic mutations) and to correlate the molecular response to HCQ and presence/absence of such mutations.

Interventions

• Drug Hydroxychloroquine Sulfate 400Mg Tab
  hydroxychloroquine sulfate tablet
• Drug Placebo
  Inactive tablet

Primary outcome measures

• Change in expression of markers of autophagy [Time frame: Day 1, Day 26/27, Day of surgery(approximately day 30)]

Secondary outcome measures (4)

• Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [Time frame: Day 1 through post surgery visit(approximately day 60)]
• Evaluate the concentration of hydroxychloroquine [Time frame: Day 1, Day 26/27, Day of surgery(approximately day 30)]
• Measure the tumor mutational burden [Time frame: Baseline and Day of Surgery(approximately Day 30)]
• Correlation between tumor mutations and HCQ responses [Time frame: Baseline and Day of Surgery(approximately Day 30)]

Eligibility criteria

Inclusion criteria

• All patients must have pathological confirmation of adenocarcinoma of the prostate Gleason score 6 (grade Group 1) or greater.
• Patients must have resectable prostate cancer as defined by the AJCC (American Joint Committee on Cancer) TNM system and have planned radical prostatectomy.
• Patients must have sufficient tissue from the initial diagnostic prostate biopsy, as determined by the study pathologist, to perform the required study analyses without exhausting the tissue required for clinical purposes
• Age >18 years
• Adequate hematopoietic, hepatic and renal function documented prior to study entry to include: Hb. > 10g/dL, WBC > 3500/mm3, ANC > 1500/mm3 and platelets > 100,000/mm3; hepatic transaminases (AST or ALT) ≤ 2.0 times the upper limits of normal, total bilirubin ≤ 1.5 times the upper limits of normal, estimated creatinine clearance ≥ 60 mL/min or eGFR > 60 mL/min/1.73 m2 and normal serum cations (K+/Mg2+/Ca2+)
• All patients must be medically fit candidates for radical prostatectomy.
• A patient with any retinopathy will only be enrolled into the study with the approval of a board-certified ophthalmologist
• All patients must give informed consent indicating they are aware of the investigational nature of this study treatment prior to any study procedures being performed.

Exclusion criteria

• Patients may not have received radiation therapy for their prostate cancer.
• Patients may not have received chemotherapy for their prostate cancer.
• Patients with gastrointestinal abnormalities including: inability to take oral medication, requirement for intravenous alimentation, or prior major surgery or diseases which may cause malabsorption (e.g. bowel resection, ischemic bowel, Crohns or Ulcerative colitis)
• A serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment will be excluded.
• Patients with significant cardiac disease: including uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous 3 months, or serious cardiac arrhythmias, including a QT interval corrected for heart rate using the Fridericia formula of ≥ 450 ms, or history of Torsade de pointes will be excluded.
• Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol will be excluded.
• Patients receiving any disease-modifying anti-rheumatic drugs (DMARDs) will be excluded.
• Patients with known or a history of G6PD deficiency will be excluded. Eligible patients will be based on clinician-investigator assessment, that the patient is not at an increased risk for G6PD deficiency (assessment should include information regarding self-reported race/ancestry), OR the patient has a negative screening test for G6PD deficiency.
• Patients taking other commercially available medications which may theoretically either stimulate or inhibit autophagy (calcitriol and chloroquine) will be excluded.
• Patients chronically taking drugs known to cause torsades de pointes will be excluded unless those agents can be discontinued for a period > 6 times their half-life before study enrollment
• Patients with poorly controlled diabetes mellitus will be excluded.
• Patients with a history of epilepsy will be excluded.
• Patients with a history of porphyria will be excluded

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Triple blind

Primary purpose

Basic science

Study locations

United States · 1 center

• Dartmouth-Hitchcock Medical Center — Lebanon

Identifiers

NCT: NCT06408298 · 23LEW054|STUDY02002054

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗